* PR used the EGM to BS to the attendees with his used car salesman-like selling skills and his delay and deflection tactics, as well as dangling a carrot just out of reach which his vague promises of announcements and a webinar soon. It's a great pity that he can't market the company to pharma's and funders, like he has been able to do to shareholders. They don't accept his BS like the shareholders have been accepting over the past 8 years.
* As for the science... seriously, until the peer-review gets done, we have nothing, except a phase II trial that didn't meet the endpoints. Let's hope the P3 results are significantly better than the most recent P2. I have had a few of my patients do reasonably well using iPPS however I've had a few get minimal to no benefit as well as quite a few getting varying amounts of irritation at the site of injection.
PAR Price at posting:
29.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)